CMMC Phase 1 officially began on November 10, 2025, but many defense contractors are still unsure if they’re fully ready for it. The confusion is understandable considering the years of delays and ...

Vigil Neuroscience reported positive Phase 1 trial results for VG-3927 and plans a Phase 2 trial in Q3 2025. Vigil Neuroscience, Inc. announced promising outcomes from a Phase 1 clinical trial of ...

Terns Pharmaceuticals announced significant updates regarding TERN-601, a novel oral GLP-1R agonist, following a successful Phase 1 clinical study and the completion of enrollment in its Phase 2 ...

Casdatifan, an HIF-2α inhibitor, showed a 33% objective response rate in ccRCC patients at a 100 mg daily dose. The drug targets hypoxia-inducible factor-2 alpha to disrupt tumor-promoting mechanisms ...

Construction of the second phase has already begun, adding six additional buildings to the campus. Crusoe announced the second phase of construction, which includes six additional buildings, expanding ...

PLYMOUTH, Mass.--(BUSINESS WIRE)--IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing precision therapeutics for the treatment of cancers with ...

Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in a hefty $215 million series B fundraise. The biotech said it would use the cash to “further ...